- Home
- IPHA vs VIGL Comparison
IPHA vs VIGL Comparison
Compare IPHA & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- VIGL
- Stock Information
- Founded
- IPHA 1999
- VIGL 2020
- Country
- IPHA France
- VIGL United States
- Employees
- IPHA N/A
- VIGL N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- VIGL Health Care
- Exchange
- IPHA Nasdaq
- VIGL Nasdaq
- Market Cap
- IPHA 160.1M
- VIGL 134.9M
- IPO Year
- IPHA 2019
- VIGL 2022
- Fundamental
- Price
- IPHA $1.71
- VIGL $7.96
- Analyst Decision
- IPHA Strong Buy
- VIGL Buy
- Analyst Count
- IPHA 1
- VIGL 7
- Target Price
- IPHA $11.00
- VIGL $8.00
- AVG Volume (30 Days)
- IPHA 11.8K
- VIGL 1.5M
- Earning Date
- IPHA 03-27-2025
- VIGL 08-12-2025
- Dividend Yield
- IPHA N/A
- VIGL N/A
- EPS Growth
- IPHA N/A
- VIGL N/A
- EPS
- IPHA N/A
- VIGL N/A
- Revenue
- IPHA $20,831,349.00
- VIGL N/A
- Revenue This Year
- IPHA $209.83
- VIGL N/A
- Revenue Next Year
- IPHA $83.15
- VIGL N/A
- P/E Ratio
- IPHA N/A
- VIGL N/A
- Revenue Growth
- IPHA N/A
- VIGL N/A
- 52 Week Low
- IPHA $1.29
- VIGL $1.31
- 52 Week High
- IPHA $3.51
- VIGL $7.96
- Technical
- Relative Strength Index (RSI)
- IPHA 37.96
- VIGL 88.44
- Support Level
- IPHA $1.72
- VIGL $7.86
- Resistance Level
- IPHA $1.88
- VIGL $7.90
- Average True Range (ATR)
- IPHA 0.08
- VIGL 0.03
- MACD
- IPHA -0.02
- VIGL -0.20
- Stochastic Oscillator
- IPHA 28.23
- VIGL 91.67
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.